Atopic Dermatitis Journal Articles

• Shingles Prevention in Immunocompromised Dermatology Patients Many immunomodulatory medications used in dermatology can increase the risk of herpes zoster. Review the use of the recombinant zoster vaccine in patients receiving these drugs.
  Skin Therapy Letter, November 03, 2023
• Utilization of Topical Ruxolitinib in Dermatology This review summarizes the use of topical ruxolitinib, a JAK inhibitor, in various dermatological conditions including vitiligo, alopecia areata, atopic dermatitis, psoriasis, and more.
  Skin Therapy Letter, September 04, 2023
• Laundry Detergent as a Cause of Allergic Contact Dermatitis While laundry detergent is often believed to be a cause of allergic contact dermatitis, evidence suggests that the prevalence of detergent-associated ACD is much less than widely assumed.
  Cutis, August 16, 2023
• Evolving Story of JAK Inhibitors for Treating Alopecia Areata Review the introduction of Janus kinase inhibitors and their application as the first-line therapeutic option for severe alopecia areata. What might be the future role of JAK inhibitors in this area?
  Skin Therapy Letter, August 03, 2023
• Mpox in Young Woman With No Epidemiologic Risk Factors An mpox diagnosis was confirmed in a young woman who presented with a facial rash with no known risk factors.
  Emerging Infectious Diseases, June 22, 2023
• Antibiotic Resistance in Dermatology: Combating Resistance It's crucial that dermatologists aim to combat antibiotic resistance, given the high use of antibiotics in dermatology. Review the appropriate use of antibiotics in common dermatoses in this paper.
  Skin Therapy Letter, June 01, 2023
• Pyoderma Gangrenosum in a Patient With Dubowitz Syndrome This case report describes the presentation of pyoderma gangrenosum in a patient with Dubowitz syndrome. Are these two conditions connected?
  Wounds, May 10, 2023
• Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Adults Review evidence from the latest clinical trials of tralokinumab, a new systemic interleukin-13 inhibitor for moderate-to-severe atopic dermatitis.
  Skin Therapy Letter, April 03, 2023
• The Influence of COVID-19 Disease on Asthma What have we learned about the impacts of the COVID-19 virus infection among people with asthma?
  BMC Pulmonary Medicine, March 24, 2023
• Tumor Treating Fields With Radiation for Glioblastoma Are there benefits to the concurrent delivery of radiation therapy with tumor treating fields? Does current evidence support this approach?
  Chinese Clinical Oncology, March 16, 2023
• Dietary Triggers for Atopic Dermatitis in Children While food allergies are often suspected of being the cause of atopic dermatitis in children, true true food-triggered AD is surprisingly rare, as discussed in this paper.
  Cutis, March 01, 2023
• Cholinergic Urticaria: Classification and Clinical Approach This paper summarizes current understanding of the etiology of cholinergic urticaria and its various subtypes. How should therapeutic management be approached for each specific subtype?
  American Journal of Clinical Dermatology, February 10, 2023
• Extracorporeal Photopheresis and Its Use in Dermatology While cutaneous T-cell lymphoma remains the only FDA approved use of extracorporeal photopheresis, it has potential as an off-label treatment for numerous dermatological conditions.
  Skin Therapy Letter, January 18, 2023
• Experience of Super-Responders to Biologics in Severe Asthma A new study provides insight into the profound impact of biologic treatment for severe asthma among super responders -- from the patient's perspective.
  BMC Pulmonary Medicine, January 13, 2023
• Environmental Persistence of Mpox Virus on Surfaces A new report finds that mpox can survive on surfaces in certain circumstances, highlighting the potential exposure risk for other household members.
  Emerging Infectious Diseases, January 10, 2023
• Dermatologic Disease in Service Members and Mental Health This article explores the relationship between common dermatoses, reduced satisfaction with cutaneous body image, and increased risk for mental illness, self-harm, and suicide in military personnel.
  Cutis, October 19, 2022
• Tirbanibulin for the Treatment of Actinic Keratosis Review the pharmacokinetics and a summary of the clinical trials of tirbanibulin 1% ointment, a new topical therapy for actinic keratosis.
  Skin Therapy Letter, October 14, 2022
• Direct-to-Consumer Teledermatology Growth This paper explores the recent and rapid expansion of direct-to-consumer teledermatology services. What are the risks and benefits of these platforms?
  Cutis, October 05, 2022
• Airborne Anaphylaxis: Highlighting an Invisible Enemy Although rare, anaphylactic reactions to airborne allergens do occur and can be potentially deadly. Learn about the potential causes and how to recognize this disorder.
  Current Opinion in Allergy and Clinical Immunology, September 30, 2022
• An Update on JAK Inhibitors in Skin Disease This paper summarizes recent trials of JAK inhibitors tested in patients with moderate to severe atopic dermatitis, including topical RUX, oral abrocitinib, upadacitinib, and baricitinib.
  Cutis, September 28, 2022